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1. Introduction 
In previous reports the feasibility of specifically 
removing circulating DNA antibodies in vivo with an 
immwnoadsorbent was demonstrated [l-3]. The 
selective removal of antigens and antigen-antibody 
complexes from the circulation in immune complex 
disease would be another desirable therapeutic goal. 
Cuprophan (Enka Glanzstoff, AC, Munich, West 
Germany), a non-toxic cellulosic membrane 
commonly employed in hemodialysis, has 
demonstrated a capacity to non-specifically adsorb 
proteins [4] and would thus appear to be a 
potential solid support for antibody adherence. 
We herein demonstrate that rabbit gamma globulin 
(RGG) may be conjugated to Cuprophan columns 
and that these RGG columns are capable of 
withdrawing specific antigen from plasma 
circulated through them. 
2. Methods, results and discussion 
Cuprophan columns 8 cm in length and 0.9 cm 
in diameter (surface area 22 cm’ ) as shown in fig. 1. 
Teflon tips were prewrapped wiih Cuprophan 
strips, moistened with 0.1 M phosphate buffer pH 
7.0 and dried on the tubing to facilitate attachment of 
the Cuprophan sheets. The latter were rolled over 
the prewrapped Teflon tips which were separated by a 
glass rod. The Cuprophan sheets overlying the 
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Teflon tips were moistened with 0.1 M phosphate 
buffer pH 7.0 and dried, resulting in its firm 
adherence to the Teflon. The glass rod was 
withdrawn and the connection between the 
Cuprophan and Teflon tubing was then wrapped 
with Parafilm (American Can Co., Neenah, Wise.). 
Finally, a strip of Teflon tape was applied to the 
exterior seam of the Cuprophan to provide 
stability to the column. 
The retention of RGG (Pentex, Kankakee, Ill.) 
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Fig. 1. Procedure for preparation of Cuprophan columns. 
See text for details. 
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on these Cuprophan columns was studied by adding 
15 mg in 3 ml of 0.1 M phosphate buffer pH 7.0 
with various concentrations of glutaraldehyde to 
each of 3 tubes. rzsI RGG [S] in 0.3 ml vol was 
added to each tube as a marker. The Cuprophan 
tubes were clamped over the Teflon segments to 
avoid injury to the Cuprophan and gently rocked on 
a platform rocker (Bellco Glass Inc., Vineland, N. J.) 
at 4°C for 12 h. The Cuprophan tubes were then 
cleared of solution and exhaustively washed with 
3 ml aliquots of 0.1 M phosphate buffer pH 7.0. 
The Cuprophan was detached from the Teflon 
and together with the washes and original solution 
counted in a Picker Nuclear gamma scintillation 
counter. The quantity of “‘1 RGG retained on 
the Cuprophan was calculated as a percentage of 
the total number of counts recovered in the washes 
and on the Cuprophan. Results are shown in fig.2. 
There was a three-fold increase in RGG uptake on 
columns exposed to RGG alone, resulting in the 
retention of 3.3 mg of RGG. 
As a preliminary to in vivo studies, antibodies to 
bovine serum albumin (BSA, Pentex, Kankakee, I1 1.) 
were obtained from a repetitively immunized rabbit 
and isolated by the method of Ishizaka et al. [6]. 
Ten ml (9 mg) of purified antibodies to BSA 
exhibited an antigen binding capacity (ABC-33) [7] 
of 33 pg of BSA bound/ml of undiluted antibody 
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Fig. 2. Progressive rise in the percentage of 15 mg RGC 
retained by Cuprophan columns as it was incubated with 
increasing quantities of glutaraldehyde. 
solution. For in.vivo studies, six Cuprophan columns 
were prepared. To each of three, 3 mg of purified 
rabbit anti-BSA antibodies, 12 mg of RGG and 15 mg 
of glutaraldehyde in 3 ml of 0.1 M phosphate buffer 
pH 7.0 were added and the columns were rocked 
at 4°C for 12 h. Fifteen mg of RGG with 15 mg of 
glutaraldehyde was added to each of three control 
columns and similarly rocked. The Cuprophan 
columns were then individually washed with 200 ml 
DOG 
CUPROPHAN COLUMNS 
Fig. 3. Experimental design for extracorporeal system is shown. Canine plasma (100-200 ml) extracted from the femoral 
artery was separated from whole blood, placed in beaker and circulated by dual channel pump through experimental and 
control columns. See text for additional details. 
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Table 1 
“‘I %A absorbed by Cuprophan columnsa 
January 1976 
Background Column 1 Column II Column 111 
Total lz51 BSA 
bound to 
Cuprophan 
Anti BSA 
Membranes 
90 
Normal RGG 
Membranes 
90 112 319 
- 
aEach Cuprophon column was detached and counted for 1 min in a gamma scintillation counter. Values 
represent he mean of four determinations. 
of 0.9% saline solution and connected with poly- 
ethylene tubing to a Travenol dual channel hemo- 
dialysis pump (fig.3). A 14 kg mongrel dog was 
premeditated with sodium pentabarbital and 
sodium heparin (1000 units/kg), and the femoral 
artery and vein cannulated with hemodialysis 
catheters (cobe Laboratories, Denver, Colo.). Ten 
minutes later 12’1 BSA (0.8 c(g) [S] was administered 
intravenously. Whole blood (100-200 ml) was 
withdrawn at 30 to 60 min intervals from the 
femoral artery. Plasma was separated from cells by 
centrifugation at 2000 rev/min for 7 min, placed 
in the beaker and circulated &rough the dual 
channel pump system for 15 to 30 min at a flow 
rate of 70 ml/min. The cells and plasma were 
then recombined, returned to the dog by the 
femoral vein and the process repeated until the 
calculated total plasma volume had been 
circulated through the columns. At the conclusion 
of the experiment, the Cuprophan columns were 
detached and individually counted in a Picker 
Nuclear gamma scintillation counter. Results 
shown in table 1 demonstrate that each of the 
experimental columns retained four-fold more 
1251 BSA than its corresponding control column. 
There were no significant alterations in hematocrit, 
platelet, leukocyte counts, sodium, potassium, 
calcium, magnesium, blood urea nitrogen and 
creatinine values during the procedure. 
The foregoing experiments demonstrate that 
antibodies may be conjugated to Cuprophan and 
that their uptake may be augmented threefold by 
the addition of glutaraldehyde, an intermolecular 
cross-linking agent [8]. When anti-BSA antibodies 
were coupled to Cuprophan they retained sufficient 
activity to withdraw four-fold more specific antigen 
from circulating plasma than RGC. 
The surface area of the experimental columns 
used in this model system was 22 cm’. We are 
presently investigating the use of markedly increased 
surface areas approximating the 18 000 to 22 000 
cm2 found in Cuprophan hemodialyzers. These will 
provide more antibody binding sites for withdrawal 
of circulating antigens. 
Plasma instead of whole blood was used for 
passage through the Cuprophan columns since 
preliminary experiments had suggested that bound 
antibody was not functional in the presence of 
cellular debris that non-specifically adsorbed to 
Cuprophan. Indeed, mechanical systems are 
presently avaliable which permit separation of plasma 
from cells and might allow contact of plasma alone 
with the immunoadsorbent surface. 
It might be of value to examine a similar approach 
as a therapeutic measure in some neoplastic diseases 
wherein circulating antigens appear to suppress the 
immune response [9,10] and in diseases mediated by 
immune complexes in antigen excess [ 111, Perhaps, 
a composite system with separate columns 
incorporating specific antigen and antibody would 
be most effective in the removal of pathogenic 
immune substances from the blood in autoimmune 
and neoplastic diseases. Studies are presently 
underway examining the practicality of removing 
specific pathogenic antigens in animal models of 
neoplasia and systemic lupus erythemotosus. 
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